Takara BioFRA:TF2 71 EBITDA Margin % is 10.51% as of Mar. 2026, which is 53% below its 10-year median of 22.55. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.45 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, Takara Bio ranks better than 63.6% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Takara Bio's EBITDA for the
three
months ended in Mar. 2026 was €6.8 Mil. Takara Bio's Revenue for the
three
months ended in Mar. 2026 was €65.0 Mil. Therefore, Takara Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 10.51%.
Takara Bio (FRA:TF2) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Takara Bio EBITDA Margin % Related Terms
Takara Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Takara Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Takara Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Takara Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a EBITDA Margin % of 10.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Takara Bio and its competitors. This is 53% below median its historical median of 22.55. According to the industry distribution chart, Takara Bio ranks #344 out of 945 companies in the Biotechnology industry, placing it in the top 36.4%.
Is Takara Bio's EBITDA Margin % too high?
Takara Bio's current EBITDA Margin % of 10.51% is 53% below median its 10-year median of 22.55. Based on the distribution chart, Takara Bio ranks #344 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #344 out of 945 companies for EBITDA Margin %. This puts Takara Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Takara Bio and its competitors. Takara Bio's current EBITDA Margin % is 10.51%, which is 53% below median its own 10-year median of 22.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.45, compared to a current price of €5.95 — trading 33.7% above its estimated fair value. The current EBITDA Margin % is 10.51%, which is 53% below median its 10-year median of 22.55. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current EBITDA Margin % is 10.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.7% above its estimated GF Value™ of €4.45.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
EBITDA Margin %: 10.51% (53% below median its 10-year median of 22.55)
GF Value™: €4.45 vs. price of €5.95 (33.7% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
